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ABSTRACT
Background Some patients with refractory asthma
have evidence of uncontrolled eosinophilic inﬂammation
in the distal airways. While traditional formulations of
inhaled steroids settle predominantly in the large
airways, newer formulations with an extra-ﬁne particle
size have a more peripheral pattern of deposition.
Speciﬁcally treating distal airway inﬂammation may
improve asthma control.
Methods 30 patients with refractory asthma despite
high dose inhaled corticosteroids were identiﬁed as
having persistent airway eosinophilia. Following 2 weeks
of prednisolone 30 mg, patients demonstrating an
improvement in asthma control were randomised to
receive either ciclesonide 320 mg twice daily or placebo
in addition to usual maintenance therapy for 8 weeks.
The primary outcome measure was sputum eosinophil
count at week 8. Alveolar nitric oxide was measured as
a marker of distal airway inﬂammation.
Results There was continued suppression of differential
sputum eosinophil counts with ciclesonide (median
2.3%) but not placebo (median 4.5%) though the
between-group difference was not signiﬁcant. When
patients who had changed their maintenance
prednisolone dose during the trial were excluded the
difference between groups was signiﬁcant (1.4% vs
4.5%, p=0.028). Though alveolar nitric oxide decreased
with ciclesonide the value did not reach statistical
signiﬁcance.
Conclusions These data demonstrate that patients
with ongoing eosinophilic inﬂammation are not truly
refractory, and that suppression of airway eosinophilia
may be maintained with additional inhaled
corticosteroid. Further work is needed with a focus
on patient-orientated outcome measures such as
exacerbation rate, with additional tests of small
airway function.
Trial registration number NCT01171365. Protocol
available at http://www.clinicaltrials.gov.
INTRODUCTION
Patients with asthma are heterogeneous in terms of
inﬂammation in the airway and response to anti-
inﬂammatory treatment. Most patients with asthma
have predominantly eosinophilic inﬂammation,
which responds to a relatively small dose of inhaled
corticosteroid (ICS).1 There are patients however,
who continue to exhibit eosinophilic airway inﬂam-
mation despite high dose inhaled steroid,2 and who
have more marked impairment of lung function,
evidence of airway remodelling, and a higher risk
of severe or fatal asthma exacerbations.3–5 The
mechanism underlying this persistent inﬂammation
is not clear, but it is not totally steroid resistant, as
high dose parenteral steroids have been shown to
abolish airway eosinophilia in patients who have
ongoing inﬂammation despite high dose ICS.6
Non-adherence to inhaled treatment is the explan-
ation for a large number of these cases, but other
factors probably contribute.
One possible explanation is that systemic steroids
reach the small airways (<2 mm in diameter) that are
not treated by traditional formulations of ICS. They
have been largely ignored until recently, partly
because they are more difﬁcult to assess than the
larger proximal airways, but also because they were
not thought to contribute signiﬁcantly to airﬂow
obstruction. Improvements in imaging and immuno-
histochemical techniques have provided a growing
body of data to support the idea that the peripheral
airways are sites of signiﬁcant inﬂammation and
physiological dysfunction in asthma,7–13 and that
current ﬁrst-line inhaled anti-inﬂammatory formula-
tions are not delivering the drug to the distal parts of
the lung.14–16
Steroid probably needs to be deposited in the
large and small airways to achieve optimal thera-
peutic effect. The distribution of an ICS within the
airway is related to particle size. Higher rates of
peripheral deposition are seen as the particle size
gets smaller with an optimum size of
Key messages
What is the key question?
▸ Does treatment with an extra-ﬁne particle size
inhaled steroid reduce airway eosinophilia in
patients with ongoing sputum eosinophilia
despite high dose inhaled steroids?
What is the bottom line?
▸ Sputum eosinophils improved signiﬁcantly in
patients who did not change their baseline
maintenance steroid dose, but markers of distal
airway inﬂammation did not change
signiﬁcantly.
Why read on?
▸ Patients with persistent airway eosinophilia are
not refractory to treatment, and targeting this
group with higher doses of steroid is likely to
be beneﬁcial.
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1.0–1.2 mm.17 While older metered dose inhalers (MDIs) which
used chloroﬂuorocarbons (CFCs) as propellants had a relatively
large median particle size, newer MDIs use hydroﬂuoroalkanes
(HFAs) which generate extra-ﬁne particles and improve total
lung deposition.18
This pilot study was designed to determine whether the intro-
duction of extra-ﬁne ICS could maintain the beneﬁcial effects
seen from a 2-week course of oral prednisolone in patients on
high dose inhaled steroids. To maximise our chances of success
we initially phenotyped patients and only included those with
evidence of persistent eosinophilic inﬂammation.
METHODS
Subjects meeting the ATS criteria for refractory asthma with evi-
dence of ongoing eosinophilic inﬂammation (sputum differential
cell count ≥3% or blood eosinophils ≥0.4×109/mL) were
recruited from difﬁcult asthma clinics in Nottingham and
Leicester between November 2010 and August 2013.19
Exclusion criteria included active smoking or a smoking history
in excess of 10 pack-years, allergic bronchopulmonary aspergil-
losis or clinically signiﬁcant bronchiectasis. All potential partici-
pants provided written informed consent and were assessed for
treatment adherence using prescribing records from primary
and secondary care. Baseline measurements were taken of bron-
chial and alveolar exhaled nitric oxide (NO), Juniper Asthma
Control Questionnaire (ACQ) score, Juniper Asthma Quality of
Life Questionnaire (AQLQ) score, and spirometry including
bronchodilator reversibility.
All potential trial participants (n=32) were given treatment
with 2 weeks of prednisolone 30 mg daily and assessed for clin-
ical improvement prior to randomisation. Clinical improvement
was deﬁned as any one of:
▸ Normalisation (<25 ppb) or a reduction in concentration of
exhaled NO of ≥40%,20
▸ An increase in prebronchodilator forced expiratory volume
in 1 s (FEV1)
▸ An improvement in Juniper ACQ score of ≥0.5 points.22
Subjects who met these criteria (n=30) underwent further
sputum induction, and were then randomised in a double-blind
manner to receive either ciclesonide 320 mg twice daily or
placebo for 8 weeks in addition to their usual maintenance medi-
cation; including high dose ICS with or without low dose oral
prednisolone. Randomisation was performed in permuted blocks
of 10 by the University of Nottingham Clinical Trials Unit.
Subjects underwent instruction and assessment of inhaler tech-
nique with the trial drug MDI, and those that were unable to
achieve an adequate technique with additional instruction (n=4)
were issued an AeroChamber Plus (GSK, Middlesex, UK).
The primary outcome measure was the change in sputum dif-
ferential eosinophil count between randomisation and week
8. Secondary outcome measures were ACQ score, AQLQ score,
prebronchodilator FEV1, bronchial NO and alveolar NO at
week 8. Safety outcome measures included adverse events and
serum cortisol level at week 8. Subjects attended trial visits at
week 4 and week 8, with assessment of secondary outcome
measures and adverse events at both visits and further sputum
induction at week 8. Subjects attended a ﬁnal follow-up visit at
week 12 to reassess secondary outcome measures and adverse
events after discontinuation of the trial drug.
Exhaled NO
Measurement of exhaled NO levels was performed using the
NIOX Flex (Aerocrine AB, Solna, Sweden). Exhaled NO levels
were measured at multiple ﬂows (10 ml/s, 30 ml/s, 50 ml/s,
100 ml/s, 200 mL/s). Exhaled bronchial NO at 50 mL/s (FeNO)
was taken as the mean value of two blows. Alveolar NO concen-
tration (Calv) was corrected for axial back diffusion as described
by Kerckx et al.23 Two adequate blows at three different ﬂow
rates were considered the minimum required to calculate a value
for alveolar NO.
Lung function
Spirometry was performed as per American Thoracic Society/
European Respiratory Society guidelines,24 using a Vitalograph
Gold Standard wedge bellows spirometer (Vitalograph,
Buckingham, UK). Subjects were instructed to omit their short-
acting bronchodilators for 4 h and their long-acting bronchodi-
lators for 12 h prior to the study visit. For reversibility testing
salbutamol was administered as 4×100 mg inhalations from an
MDI via a spacer device, with repeat spirometry after a
minimum of 15 min.
Asthma control and quality of life
Asthma control was assessed using a self-completed ACQ ques-
tionnaire. A score of ≥1.5 was used to deﬁne poorly controlled
asthma, as this is safely within the uncontrolled range, and is the
lowest value at which a clinically signiﬁcant change in score
takes the subject into the ‘controlled’ range.22 Quality of life
was assessed using a self-completed AQLQ questionnaire.25
Sputum differential cell count
Inﬂammatory phenotyping was performed using sputum induc-
tion to obtain a differential cell count. The protocol for sputum
induction and processing has been previously described,26 and
uses a low-output ultrasonic nebuliser to deliver hypertonic saline
at increasing concentrations. Subjects were classed as eosinophilic
if their differential sputum eosinophil count was ≥3%.27
Statistical analysis
Statistical analysis was performed using Stata SE V.11.2
(Statacorp, Texas, USA). Data for exhaled NO (FeNO) were log
transformed to normality prior to analysis. Corrected alveolar
NO, differential cell counts for blood and sputum and serum
cortisol could not be transformed to normality and were ana-
lysed as non-parametrical data. Based on data with a similar
cohort of patients,6 16 patients per group would allow detection
of a 40% reduction in sputum eosinophil count at 80% power,
assuming a median sputum eosinophil count at baseline of 25%.
We planned to recruit 20 patients per group to allow for
dropouts.
Within-group change was assessed using a paired samples t test
for parametrical data and a Wilcoxon signed-rank test for non-
parametrical data. Between group differences were assessed using
an independent samples t test for parametrical data and a
Mann-Whitney U test for non-parametrical data. Changes in log-
transformed values for FeNO were expressed as fold change using
the antilog of the mean difference, along with the 95% CI.
Due to the short nature of the study participants on oral
prednisolone were asked to avoid changing their maintenance
dose during the study. Unfortunately ﬁve patients did change
their maintenance dose during the trial period and so a post
hoc, per-protocol analysis was performed evaluating patients
who maintained a stable maintenance dose throughout the trial.
RESULTS
Forty-seven patients were approached to take part in the study
between December 2010 and August 2013. Thirteen subjects
were excluded as they did not have evidence of persistent
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eosinophilic inﬂammation. Two subjects did not meet our pre-
speciﬁed criteria for a clinical response to prednisolone, and a
further two subjects declined to take part. Thirty subjects were
randomised to receive ciclesonide (n=15) or placebo treatment
(n=15) and 29 completed all of the study visits (ﬁgure 1).
Recruitment was closed before the target of 40 patients was
reached due to expiry of active and placebo inhalers.
Prior to treatment with prednisolone the two groups were
comparable (table 1). Subjects were already receiving high dose
inhaled steroid (median 1600 mg of BDP or equivalent daily)
and a third were using maintenance prednisolone. For the
patient group as a whole there was a signiﬁcant improvement in
sputum eosinophil count, lung function, asthma control and
quality of life after 2 weeks of prednisolone (table 2, ﬁgure 2).
Twenty-four out of 30 subjects (80%) were able to provide a
second sputum sample at week 8. The median sputum eosino-
phil count in the ciclesonide group was 2.3% (IQR 0.5–13.5%),
an increase of 2.3% from the postprednisolone value
(p=0.263). In the placebo group the median sputum eosinophil
count at week 8 was 4.5% (IQR range 1.0–9.5%), an increase
of 4.5% from the postprednisolone value (p=0.041). Though
ciclesonide maintained sputum eosinophils at <3% the
between-group difference was not signiﬁcant (p=0.317; table 3,
ﬁgure 3). There was a trend towards lower corrected alveolar
NO in the ciclesonide group at week 8, but the difference did
not reach statistical signiﬁcance.
There was no signiﬁcant decline in lung function, asthma
control, quality of life or exhaled NO in either group (table 3).
Though there was a trend towards worsening asthma control in
the placebo group this was not signiﬁcant (change in ACQ 0.7,
p=0.051). Ciclesonide was well tolerated, with no dropouts due
to adverse effects and no signiﬁcant suppression of serum corti-
sol (median change from baseline −62 nmol/L, p=0.327 vs
+34 nmol/L in the placebo group, p=0.953). Though more
subjects in the placebo group reported worsening breathlessness
or wheeze in the 8-week trial period (4 vs 1 in the ciclesonide
group) this was not signiﬁcant.
Effect of change in maintenance steroid
Although all subjects were requested to try and keep their main-
tenance dose of oral prednisolone constant during the study,
ﬁve subjects (three in the placebo group and two in the cicleso-
nide group) were taking a higher than usual maintenance dose
of steroid at the week 8 visit. In addition, one subject in the
ciclesonide group felt well enough to stop their maintenance
steroid dose during the trial period and experienced an exacer-
bation just before week 8 (see ﬁgure 3). As this is very likely to
have an effect on the outcome measures for airway inﬂamma-
tion at week 8 an additional per-protocol analysis was per-
formed excluding these patients.
Again, there was a signiﬁcant rise in sputum eosinophils over
8 weeks with placebo (4.5%, p=0.014) which was not seen in
the ciclesonide group (table 4) and the between-group differ-
ence was signiﬁcant (p=0.028). There remained no signiﬁcant
differences between groups for any of the secondary outcome
measures.
Figure 1 Consort ﬂow diagram. Two patients in the run-in period did not reach our prespeciﬁed criteria for clinical improvement despite a
reduction in sputum eosinophils. One patient in the placebo group dropped out in week 3 but was included in the ﬁnal intention-to-treat analysis.
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DISCUSSION
The run-in data from this study demonstrates that subjects with
persistent eosinophilic inﬂammation remain responsive to add-
itional corticosteroid, and that 2 weeks of systemic corticoster-
oids largely eliminates airway eosinophilia while improving
asthma control, quality of life and lung function. These changes
are unlikely to be fully explained by poor inhaler technique or
non-adherence to treatment, as these factors were accounted for
before the subjects were entered into the trial. The beneﬁts seen
in the run-in period with oral prednisolone were maintained
after 8 weeks with the addition of ciclesonide to regular mainten-
ance therapy whereas sputum eosinophilia was reappearing in
patients treated with placebo. When changes to oral maintenance
therapy were accounted for there was signiﬁcantly less airway
eosinophilia with ciclesonide compared with placebo.
The main limitations of our study include its size, duration
and the lack of a third limb containing standard formulation
inhaled steroid. Studying patients with severe asthma is difﬁcult
and so before attempting a much larger, longer study, powered
to see a difference in asthma control, we felt it was essential to
ﬁrst demonstrate proof of concept in a pilot study using the
proxy marker of sputum eosinophilia. The beneﬁcial effects
from the addition of high dose inhaled ciclesonide on sputum
inﬂammation may simply result from the addition of more
inhaled steroid. There is however limited evidence of a dose
response curve for standard inhaled steroids after approximately
1000 mg beclometasone dipropionate (BDP) or equivalent,28 29
and patients in our study were already using up to 4000 mg
daily. We, therefore, postulate that the beneﬁcial effects on
sputum eosinophilia seen here could be secondary to the intro-
duction of a ﬁne-particle inhaled steroid, with improved depos-
ition throughout the lung including the distal airways. We
included measurements of alveolar NO to explore this hypoth-
esis further but the results were inconclusive and do not help
differentiate a small airway from a more general anti-
inﬂammatory effect. We did not include other markers of small
airway dysfunction as none have been validated and most are
relatively difﬁcult to use in patients with more severe asthma.
The evidence for distal airway disease in some patients with
difﬁcult to control asthma is compelling. Patients with predom-
inantly nocturnal asthma have evidence of marked eosinophilic
inﬂammation in the distal, but not the proximal airways when
biopsy samples are compared, with a fourfold increase in alveo-
lar eosinophils correlating with worsening lung function and
an increase in symptoms.13 This is not accompanied by an
increase in peripheral blood eosinophils, suggesting it is an accu-
mulation in the alveolar tissue rather than a general
Table 1 Baseline characteristics
Ciclesonide (n=15) Placebo (n=15)
Age (years)* 48.5 (11.6) 53.3 (13.3)
Female (%) 7 (47%) 7 (47%)
BMI* 29.9 (4.6) 27.3 (4.6)
ICS dose (mg BDP)† 1600 (1200–2000) 1600 (1000–2000)
Regular prednisolone (%) 6 (40%) 4 (27%)
Prednisolone dose (mg)† 5 (5–10) 5 (5–10)
FEV1 (L)* 2.0 (0.6) 1.8 (0.6)
FEV1 (% predicted)* 61.8 (14.9) 60.1 (9.4)
ACQ score* 3.2 (1.0) 2.8 (0.8)
AQLQ score* 4.0 (1.1) 4.3 (1.1)
FeNO (ppb)‡ 58.9 (0.3) 43.7 (0.3)
Corrected alveolar NO (ppb)† 3.3 (0.6–6.4) 2.6 (1.4–4.5)
Sputum eosinophils (%)† 23 (7.5–51.1) 9.6 (6.8–31.5)
Sputum neutrophils (%)† 43.5 (27.5–73.0) 50.5 (31.8–70.5)
Blood eosinophils (×109/L)† 0.5 (0.5–0.9) 0.4 (0.2–0.7)
Blood neutrophils (×109/L)† 4.5 (3.6–6.3) 5.0 (3.7–6.6)
Serum cortisol (nmol/L)† 266 (217–414) 254 (191–294)
*Mean (SD).
†Median (IQR).
‡Geometric mean (log SD).
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire;
BDP, beclometasone dipropionate; BMI, body mass index; FeNO, fractional exhaled nitric
oxide; FEV1, forced expiratory volume in 1 s; ICS, inhaled corticosteroid; NO, nitric oxide.
Table 2 Response to 2 weeks of prednisolone during the run-in
period for all subjects (n=30)
Baseline
(preprednisolone)
Randomisation
(postprednisolone) p Value
Sputum
eosinophils (%)*
16 (7.3–38.0)
(n=29)
0 (0–2.3)
(n=21)
<0.001
Sputum
neutrophils (%)*
44.5 (31.8–70.5)
(n=29)
78.3 (56.9–94.0)
(n=21)
0.005
FEV1 (litres)† 1.9 (0.6) 2.4 (0.7) <0.001
ACQ score† 3.0 (0.9) 1.5 (0.9) <0.001
AQLQ score† 4.1 (1.1) 5.6 (1.1) <0.001
FeNO (ppb)‡ 50.9 (0.3) 31.7 (0.3) <0.001
Corrected alveolar
NO (ppb)*
2.7 (1.3–6.4) 1.9 (0.9–2.9) 0.049
*Median (IQR).
†Mean (SD).
‡Geometric mean (log SD).
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire;
FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s;
NO, nitric oxide.
Figure 2 Sputum eosinophil count before and after 2 weeks of
prednisolone.
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inﬂammatory response.30 There is evidence of physiological dys-
function as well as inﬂammation in the small airways in subjects
with asthma. Wagner et al9 used a wedged bronchoscope with a
double lumen catheter to measure airway resistance in the small
airways. Subjects with asymptomatic asthma and normal spirom-
etry were compared with control subjects, and were found to
have more than a sevenfold increase in peripheral airway resist-
ance, suggesting a degree of disease activity not detected by
traditional measures of lung function. Reduction in elastic
recoil, which is seen in subjects with emphysema, has also been
found in patients with chronic severe asthma with normal diffu-
sion capacity and CT appearances, likely reﬂecting pathological
changes in the small airways.12
A number of studies have explored the effect of extra-ﬁne
particle size inhaled steroids on small airway function. In a
study comparing HFA-BDP with CFC-ﬂuticasone propionate
(FP), while both inhalers improved standard markers of airﬂow
obstruction in patients with moderate uncontrolled asthma, only
the HFA-BDP formulation improved closing volume to vital
capacity ratio and residual volume, both markers of small
airway dysfunction.31 Goldin et al32 used high resolution CT to
measure lung attenuation as a surrogate marker of air trapping,
and demonstrated that HFA-BDP but not CFC-BDP reduced air
trapping following methacholine challenge. In a further open-
label study, Verbanck et al33 used multiple breath nitrogen
washout to assess changes in peripheral airway function follow-
ing treatment with HFA-BDP in 30 patients with stable asthma.
Sixteen subjects with abnormal acinar ventilation at baseline
showed signiﬁcant improvement in peripheral, but not central
airway function with a switch to the extra-ﬁne steroid prepar-
ation. Yamaguchi et al34 used impulse oscillation to assess small
airway function in steroid naive patients with asthma, who were
Table 3 Primary and secondary outcome measures at randomisation and week 8
Ciclesonide (n=15) Placebo (n=15)
Randomisation Week 8 p Value Randomisation Week 8 p Value Between group p
Sputum eosinophils (%)* 0.0 (0.0–2.3)
(n=10)
2.3 (0.5–13.5)
(n=11)
0.263 0.0 (0.0–4.3)
(n=11)
4.5 (1.0–9.5)
(n=13)
0.041 0.317
Sputum neutrophils (%)* 77.5 (47.6–96.5)
(n=10)
55.8 (38.8–88.5)
(n=11)
0.017 79.5 (64.5–94.0)
(n=11)
70.5 (56.8–89.3)
(n=13)
0.799 0.155
FEV1 (litres)† 2.6 (0.7) 2.5 (0.7) 0.252 2.1 (0.7) 2.0 (0.6) 0.115 0.699
ACQ score† 1.4 (1.1) 1.8 (1.4) 0.175 1.6 (0.8) 2.3 (1.3) 0.051 0.318
AQLQ score† 5.8 (1.0) 5.4 (1.5) 0.145 5.5 (1.2) 5.0 (1.4) 0.243 0.800
FeNO (ppb)‡ 32.4 (0.4) 40.6 (0.4) 0.097 30.7 (0.3) 34.9 (0.3) 0.292 0.598
Corrected alveolar NO (ppb)* 1.7 (0.3–2.5) 1.4 (0.1–3.0) 0.925 2.0 (0.9–3.1) 2.4 (1.1–3.6) 0.730 0.528
Blood eosinophils (×109/L)* 0.1 (0.0–0.2) 0.3 (0.1–0.6) 0.013 0.2 (0.0–0.4) 0.3 (0.2–0.5) 0.065 0.128
*Median (IQR).
†Mean (SD).
‡Geometric mean (log SD).
ACQ, Asthma Control Questionnaire; AQLQ, Asthma Quality of Life Questionnaire; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 s; NO, nitric oxide.
Figure 3 Median (IQR) sputum
eosinophil count before and after
8 weeks of ciclesonide or placebo in
addition to usual treatment.
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randomised to receive either HFA-BDP or CFC-BDP for
12 weeks. At the end of the treatment period, while both
groups showed improvements in markers of large airway disease
only the patients receiving HFA-BDP showed an improvement
in small airway resistance. Others have used alveolar NO to
look for treatment effects on the small airways. Like us,
Williamson et al35 found that alveolar NO was insensitive to
changes in dose of ICSs and Gelb et al36 found no change in
alveolar NO with the addition of a leukotriene antagonist
despite small changes in spirometry. Whether alveolar NO is a
useful marker of small airway inﬂammation in much larger
studies remains to be seen.
The extra-ﬁne formulations appear to be safe and well toler-
ated, with no difference in pituitary function or urinary free cor-
tisol excretion when compared with an equivalent dose of CFC
BDP.37 There is also a lower incidence of oropharyngeal candid-
iasis and dysphonia with extra-ﬁne formulations, which may be
due to reduced deposition of drug at these sites,37 or in the case
of ciclesonide reduced drug activation outside the lung.16
The strength of this study is that we used a real-world popula-
tion of patients with severe asthma. We selected patients with evi-
dence of persistent eosinophilic inﬂammation, despite high-dose
inhaled steroids to maximise our potential for success. Although
this reduces the generalisability of our study it is in line with the
current management of severe asthma which encourages the selec-
tion of patients with speciﬁc phenotypes to maximise efﬁcacy
from novel therapies. Treatment was not withheld or withdrawn
during the study period, which reﬂects normal clinical practice,
and treatment adherence was checked thoroughly before entering
patients into the study. The difﬁculty in translating the results into
clinical practice lies in the identiﬁcation of patients with ongoing
eosinophilic inﬂammation. Though induced sputum is very effect-
ive, it is relatively labour-intensive, requiring manual cell counts,
and is not widely available. Though some clinicians advocate a
therapeutic trial of prednisolone to identify those with residual
eosinophilic inﬂammation it would mean overtreating many
patients (in this study around 30% of patients identiﬁed had
non-eosinophilic inﬂammation, see ﬁgure 1) and is not without
risk. It may be possible to identify patients with ongoing airway
eosinophilia using proxy markers such as FeNO and blood eosino-
phils, but more work is required in this area.
This was a short-term, pilot study to evaluate the effect of
ciclesonide in refractory eosinophilic asthma, and as such was
not designed to look at outcomes such as exacerbation rate.
It has been demonstrated that a treatment strategy based on nor-
malising sputum eosinophil count can signiﬁcantly reduce
asthma exacerbations and hospital admissions.27 Further work
with a longer period of follow-up is needed to establish if the
beneﬁcial short-term effects of extra-ﬁne particle size steroids
translate into a longer-term reduction in exacerbations and,
ultimately, a reduction in systemic steroid exposure. A third
treatment arm with a higher dose of a standard formulation ICS
would help to differentiate an effect on the small airways over
simply more corticosteroid in the airways. If conﬁrmed, this
approach would be safer than continuing oral prednisolone and
considerably cheaper than new biological therapies such as oma-
lizumab or anti IL-5 which also reduce asthma exacerbations.
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